Opiyat Kullanım Bozukluğu
Özet
Opiyat bağımlılığı, Papaver somniferum bitkisinden elde edilen opiyatlar ve bunların sentetik/yarı sentetik türevleri olan opioidlerin kullanımıyla ortaya çıkan, küresel düzeyde artış gösteren ve durdurulamayan kronik bir sağlık sorunudur. Dünya genelinde ve Türkiye'de epidemik rakamlara ulaşan bu bozukluk, özellikle en tehlikeli tür olan eroin ve sentetik bir opioid olan fentanil kullanımıyla öne çıkmaktadır. Etiyolojisinde dar gelirli sosyoekonomik şartlar, kaotik aile ortamları, akran etkisi gibi çevresel faktörlerin yanı sıra libidinal fiksasyonlar, dürtüsellik, antisosyal kişilik bozukluğu ve μ-opioid reseptör polimorfizmi gibi biyolojik ve genetik yatkınlıklar kilit rol oynamaktadır. Hücresel düzeyde Gi/G0 proteinlerine bağlanarak nöronal aktiviteyi baskılayan opioidler, beynin ödül sisteminde dopamin salınımını artırarak güçlü bir öfori ve ardından fiziksel bağımlılık ile tolerans geliştirir. ICD-11 ve DSM-5 kriterlerine göre tanı konulan bu rahatsızlıkta, idrar analizleri ve COWS gibi tarama ölçekleri kullanılırken; intoksikasyon durumlarında solunum depresyonu ve miyozis gibi hayati tehlikeler naloksan ve nalmefen gibi antagonistlerle tedavi edilir. Bağımlılık tedavisinde ise farmakoterapi (metadon gibi agonistler, buprenorfin gibi parsiyel agonistler ve naltrekson gibi antagonistler) ile bilişsel davranışçı terapiler, 12 basamaklı kendi kendine yardım grupları ve umut vadeden immunoterapi yöntemleri entegre edilerek hastanın dürtüsel davranışlarının engellenmesi ve yaşam biçiminin değiştirilmesi amaçlanmaktadır.
Opioid addiction is a chronic, globally increasing, and unstoppable health problem that arises from the use of opiates derived from the Papaver somniferum plant and their synthetic or semi-synthetic derivatives called opioids. Reaching epidemic numbers worldwide and in Turkey, this disorder stands out particularly with the use of heroin, the most dangerous type, and fentanyl, a synthetic opioid. In its etiology, environmental factors such as low-income socioeconomic conditions, chaotic family environments, and peer influence play a key role, alongside biological and genetic predispositions like libidinal fixations, impulsivity, antisocial personality disorder, and μ-opioid receptor polymorphism. At the cellular level, opioids bind to Gi/G0 proteins to suppress neuronal activity, increasing dopamine release in the brain's reward system to generate a strong euphoria, followed by the development of physical dependence and tolerance. In this condition diagnosed according to ICD-11 and DSM-5 criteria, urine analyses and screening scales like COWS are utilized, while life-threatening risks such as respiratory depression and miosis in cases of intoxication are treated with antagonists like naloxone and nalmefen. In addiction treatment, pharmacotherapy (agonists like methadone, partial agonists like buprenorphine, and antagonists like naltrexone) is integrated with cognitive behavioral therapies, 12-step self-help groups, and promising immunotherapy methods, aiming to prevent the patient's impulsive behaviors and modify their lifestyle.
Referanslar
Sadock BJ, Sadock VA. Kaplan&Sadock Klinik Psikiyatri. (Hamdullah Aydın, Ali Bozkurt Çev. Ed.), 2. Baskı. Ankara: Güneş Kitabevi; 2005. p.117-122.
Işık E, Uzbay T. Güncel Temel ve Klinik Psikofarmakoloji. Ankara: Golden Medya; 2009.
Bilici R. Opioid ile ilişkili bozukluklar. ( 09.02.2022 tarihinde https://www.sbu.edu.tr/FileFolder/Dosyalar/ykBkZcpZ/2018_12/opioidileiliskilibozukluklar-4e2e4222.pdf adresinden ulaşılmıştır).
Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proceedings of the National Academy of Sciences. 1993;90(12):539:1–3.
Westermayer J. Historical and Social Context of Psychoactive Substance Use Disorders. In: Clinical Textbook of Addictive Disorders Third Ed. 2005;16–32.
Karch SB. The pathology of drug abuse. New York: CRC Press. 1996;281-312.
Goldstein A. Heroin addiction: Neurobiology, pharmacology and policy. Journal of Psychoactive Drugs. 1991;23(2):123–133.
Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morbidity and Mortality Weekly Report. 2016; 65: 1445-1452.
Evren C, Ögel K, Uluğ B. Alkol Madde Bağımlılığı Tanı ve Tedavi El Kitabı. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2012.
Huecker MR, Marrafa J. "Heroin." StatPearls: StatPearls Publishing; 2019.
World Health Organization. Information sheet on opioid overdose2018..https://www.who.int/news-room/fact-sheets/detail/opioid-overdose. [Accessed: 13.02.2022]
Evren C, Ogel K, Demirci A, at al. Prevalence of lifetime tobacco, alcohol and drug use among 10th grade students in Istanbul. Journal of Clinical Psychopharmacology. 2014;24(3):201
Han B, Volkow ND, Compton WM, at al. Reported Heroin Use, Use Disorder, and Injection Among Adults in the United States, 2002-2018. JAMA. 2020;323:568-571
Substance Abuse and Mental Health Administration. National Survey on Drug Use and Health: Detailed Tables. Department of Health and Human Services. Rockville MD; 2019.
Chen LH, Hedegaard H, Warner M. Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011. NCHS Data Brief. 2014;166:1-8.
Salm-Reifferscheidt L. Tramadol: Africa's opioid crisis. Lancet. 2018; 391:1982.
Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016; 387:1644-1656.
Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. New England Journal of Medicine. 2016; 374:154-163.
Dilbaz N. Opiyat Bağımlılığı. Madde Bağımlılığı Tanı ve Tedavi Kılavuzu El Kitabı. T.C Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Ankara; 2012.
Türkiye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi (TUBİM). Bağımlılık Yapıcı Maddeler ve Bağımlılıkla Mücadelede 2006 Yılı Türkiye Ulusal Raporu. Ankara: KOM Yayınları, 2006.
Ögel K. Madde kullanımı ve bağımlılığın nedenleri. Sigara, Alkol ve Madde Kullanım Bozuklukları: Tanı, Tedavi ve Önleme. İstanbul: Yeniden Yayınları; 2010. p. 3-16.
Conway KP, Kane RJ, Ball SA at al. Personality, substance of choice, and polysubstance involvement among substance dependent patients. Drug and Alcohol Dependence. 2003;71:65-75.
DeJong CA, van den Brink W, Hartefeld FM at al. Personality disorder in alcoholics and drug addicts. Comprehensive Psychiatry. 1993;34:87-94.
Thomas VH, Melchert TP, Banken JA. Substance dependence and personality disorders: comorbidity and treatment outcome in an inpatient treatment population. Journal of Studies on Alcohol and Drugs. 1999;60:271-277.
Abay E, Ateş İ. Bağımlılığın genetiği. Bağımlılık Dergisi. 2001; 2(2):68-70.
Yüncü Z, Savaş HA. Madde kullanım bozukluklarında genetik: Bir gözden geçirme. Bağımlılık Dergisi. 2007;8: 146-152.
Kendler KS, Jacobson KC, Prescott CA, at al. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. American Journal of Psychiatry. 2003;160:687-695.
Tsuang MT, Lyons MJ, Meyer JM, at al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Archives of General Psychiatry. 1998;55:967-972.
Brown R. Heroin dependence. Wisconsin Medical Journal. 2004;103(4):20–26
Benarroch EE. Endogenous opioid systems: current concepts and clinical correlations. Neurology. 2012; 79(8):807-14.
Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proceedings of the National Academy of Sciences. 1973;70(8):2243-2247.
Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proceedings of the National Academy of Sciences. 1973;70(7):1947-1949.
Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol et Toxicologica. 1973;33(5):377-84.
Lord JA, Waterfield AA, Hughes J, at al. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977; 267(5611):495-499.
Martin WR, Eades CG, Thompson JA, at al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics. 1976; 197(3):517-532.
Benarroch EE. Endogenous opioid systems: current concepts and clinical correlations. Neurology. 2012; 79(8): 807-814.
Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annual Review of Pharmacology and Toxicology. 2000; 40: 389-430.
Mansour A, Fox CA, Akil H, at al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends in Neurosciences. 1995; 18(1):22-29.
Suzuki T, Tsuji M, Mori T. Involvement of dopamine-dependent and-independent mechanisms in the rewarding effects mediated by δ opioid receptor subtypes in mice. Brain research. 1997; 744(2): 327-334.
Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. Journal of Neuroscience. 1997; 17(2):796-803.
Matthes HW, Maldonado R, Simonin F. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene. Nature. 1996; 383(6603): p. 819.
Jaffe JH. Drug addiction and drug abuse. Gilman AG, Goodman LS, Rall TW, Murad F. (eds.) Goodman and Gilman’s The Pharmacologic Basis of Therapeutics, Seventh Edition. New York: MacMillan Publishing Company ;1985: 532-581.
Evren C. Alkol ve Madde Kullanım Bozuklukları Temel Başvuru Kitabı. Ankara: Türkiye psikiyatri derneği yayınları; 2019.
Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs. 2003;35(2):253-259.
Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors. 1990;15(5):487-490.
Skinner H. The Drug Abuse Screening Test. Addictive Behaviors. 1982; 7: 363– 371.
Peachey JE, Lei H. Assessment of opioid dependence with naloxone. British Journal of Addiction. 1988;83(2);193-201.
Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wisconsin Medical Journal. 1995; 94:135-140.
Futz JM, Senay EC. Guidelines fort he management of hospitalized narcotics addicts. Annals of Internal Medicine. 1975; 82(6): 815-818.
Setty A. Opioid abuse cause for pause among physicians. News opinion Op-Eds. Maryland heroin and opioid emergency.task.force.http://www.baltimoresun.com/news/opinion/oped/bs-ed-anesthesiologists-opioids20170111. story.html [Accessed: 13.02.2022]
Volkow ND, Jones EB, Einstein EB, at al. Prevention and treatment of opioid misuse and addiction: a review. JAMA psychiatry. 2019;76(2):208-216.
Conway KP, Compton W, Stinson FS, at al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry. 2006; 67(2):247-257.
Aiyer R, Jain V, Bhatia A, at al. Rare presentation of intrathecal morphine withdrawal psychosis. Journal of Pain and Symptom Management. 2017;7(3):171-173.
Maremmani AG, Rovai L, Rugani F, at al. Substance abuse and psychosis. The strange case of opioids. European Review for Medical and Pharmacological Sciences. 2014;18(3): 287-302.
Altuğlu İ, Tanyeri S, Zeytinoğlu A, at al. Madde kullanımı olan olgularda HBsAg, Anti-HCV ve Anti-HIV seroprevalansı: retrospektif bir değerlendirme. Archives of Neuropsychiatry. 2019; 56: 186-190.
Yalnız H, Nebioğlu M, Karacan BS, at al. Madde bağımlılığı tanısı alan gençlerde cinsel yolla bulaşan hastalıklar ve aile planlaması ile ilgili bilgi düzeyi ve verilen eğitimin etkisi. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi. 2011;24:106-12.
Fareed A, Stout S, Casarella J, at al. Illicit opioid intoxication: diagnosis and treatment. Substance Abuse. 2011;5:17-25.
Yüksel N. Ruhsal Hastalıklar. (3. Baskı). Ankara: MN Medikal &Nobel Yayıncılık; 2006.
Işık E, Işık U. Psikiyatrik belirtili bedensel bozukluklar. İstanbul: Tenedoks Yayıncılık; 2010.
Tahsili-Fahadan P, Aston-Jones G. Neurobiology of Opioid Addiction. Encyclopedia of Behavioral Neuroscience. 2010; 393–403.
Ögel K. Madde Bağımlılarına Yaklaşım ve Tedavi. İstanbul: IQ Kültür Sanat Yayıncılık; 2002.
Jaffe JH, Strain EC. Opioidlere bağlı bozukluklar. İçinde: Comprehensive Textbook of Psychiatry. (Ed): Kaplan ve Sadocks’. Ankara; Öncü Basımevi, 2007: 1265-12690.
Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. Journal of Clinical Psychopharmacology. 1992; 12(3):203-209.
Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience. 2007; 9(4):455.
Comer SD, Collins ED, Kleber HD, at al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002; 159(4): p. 351-360.
Lee JD, Nunes EV, Novo P, at al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018; 391(10118):309-318.
Tanum L, Solli KK, Latif ZH, at al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence:a randomized clinical noninferiority trial. JAMA psychiatry. 2017;74(12): 1197-1205.
Evren C, Tamar D, Babayağmur B, at al. Opioid bağımlılığının tedavisinde buprenorfin: metadonla karşılaştırma çalışmaları. Klinik Psikofarmokoloji Bülteni. 2000;10:205-212.
Wainer BH, Fitch FW, Fried J, at al. A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. Journal of Immunology. 1973; 110: 667-673.
Bonese KF, Wainer BH, Fitch FW, at al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature.1974;252:708-710.
Li QQ, Sun CY, Luo YX, at al. A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats. International Journal of Neuropsychopharmacology. 2015; 18:93.
Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics. 2005;108:76-85.
